Inhibrx Biosciences, Inc. Common Stock
INBXInhibrx Biosciences, Inc. (INBX) is a biotech company focused on developing innovative therapies primarily in the areas of oncology, immunology, and rare diseases. Utilizing a proprietary protein discovery platform, Inhibrx designs targeted biologics and therapeutic candidates to address unmet medical needs. The company aims to advance its pipeline through preclinical and clinical development, emphasizing precision medicine approaches.
Company News
Inhibrx Biosciences reported Q1 2026 results with a net loss of $33.4 million ($2.15 per share), improved from $43.3 million in Q1 2025. The company raised $75 million in debt financing, bringing cash to $161.7 million. R&D expenses decreased to $25.2 million due to lower clinical trial costs. Key programs include INBRX-106 for head and neck canc...
Inhibrx Biosciences is in early-stage discussions with multiple major pharmaceutical companies regarding a potential joint spin-off of its cancer drug INBRX-106 and another oncology asset, with combined valuations potentially exceeding $9 billion. INBRX-106 is being tested as a standalone therapy and in combination with Merck's Keytruda. The stoc...
U.S. stock markets hit record highs after September's inflation data showed a softer-than-expected 3% annual rate, boosting investor confidence in potential Federal Reserve interest rate cuts. Major indices like S&P 500 and Dow Jones reached new peaks, with technology stocks leading the rally.
Inhibrx Biosciences announced positive Phase 2 trial results for ozekibart in treating chondrosarcoma, demonstrating significant progression-free survival improvement and becoming the first experimental therapy to show such benefit in this cancer type.
JMP Securities initiated coverage on Inhibrx Inc. with a Market Perform rating following the acquisition of INBRX-101 by Sanofi. The newly formed Inhibrx Biosciences has a strong financial foundation, but faces challenges with negative profitability metrics.
